Bioventus Inc - Ordinary Shares - Class A

NASDAQ:BVS   4:00:00 PM EDT
2.20
-0.05 (-2.22%)
4:49:30 PM EDT: $2.22 +0.02 (+0.91%)
Other Pre-Announcement

Bioventus Files For Extension To File Form 10-Q For The Period Ended October 1, 2022

Published: 11/16/2022 23:05 GMT
Bioventus Inc - Ordinary Shares - Class A (BVS) - Bioventus Files for Extension to File Form 10-q for the Period Ended October 1, 2022.
Bioventus - As Result of Recent Decline in Co's Market Capitalization Subsequent to Its Results for Q3 Requires Additional Time to Complete Review.
Bioventus Inc - Requires Additional Time to Complete Review to Assess Whether a Non-cash Impairment Charge is Required for Q3 of 2022.
Bioventus Inc - Preliminary Review Indicates an Impairment Charge in Range of $185 Million to $205 Million for Q3.
Bioventus Inc - Seeking Resolution Related to Validity of a Revised Invoice Received Subsequent to Company's Q3 Earnings Release.
Bioventus - Invoice is for Rebate Claims From Large Private Payer in Relation to Pain Treatments Vertical.
Bioventus Inc - Invoice for Rebate Likely Will Adversely Affect Company's Previously Announced Q3 2022 Financial Results.
Bioventus Inc - Recognition of Additional Rebates May Impact Bioventus' Recently Announced Revenue Guidance.
Bioventus Inc - at This Time, Company Expects No Change in Its Adjusted EBITDA Guidance for Full Year 2022.
Bioventus - Concluded That Internal Controls Related to Timely Recognition of Qtrly Rebates Were Inadequate Specifically for Period Ended Oct 1, 2022.
Bioventus- Evaluating If Co Will Be Able to Meet All Financial Obligations As They Come Due Within 1-year After Statements for Period Ended Oct 1, Are Issued.